Summary
Hypertension is a major risk factor for coronary heart disease (CHD) and is the primary risk factor for stroke. Drug trials lowering blood pressure by pharmacological means have demonstrated impressive reduction in both fatal and nonfatal stroke (33 to 50%) that are virtually identical to the predicted stroke reduction, considering the observed diastolic blood pressure change (5 to 6mm Hg). On the other hand, reduction of CHD risk has been less impressive in these same trials. Although statistically significant, the reduction in CHD risk is roughly one-half (14%) of that predicted (25%) when results from these drug trials are analysed in aggregate. Most trials have used moderate to high dosages of thiazide diuretics or β-blockers as therapies. Several factors may account for the disappointing results in CHD risk reduction. These drugs may induce metabolic disturbances in lipids, increased glucose tolerance, insulin resistance, or cause inadequate regression of left ventricular hypertrophy, thus attenuating the predicted reduction in CHD risk associated with pharmacological blood pressure lowering.
Isradipine is a new dihydropyridine calcium antagonist that is highly effective in lowering blood pressure. Isradipine also has antiatherogenic properties in animal models of atherosclerosis. The effect of isradipine on atherosclerosis in humans is unknown. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) is a 3-year double-blind, randomised trial in over 800 men and women with hypertension, aged 40 years or older. The primary aim of MIDAS is to compare the efficacy of isradipine 2.5 to 5.0mg twice daily vs hydrochlorothiazide 12.5 to 25mg twice daily in retarding the progression of extracranial carotid atherosclerosis.
A sample of 883 men and women with hypertension and with demonstrated carotid plaque have been recruited and will be observed for at least 3 years. Participants are randomised into 2 parallel groups receiving either isradipine or hydrochlorothiazide. The primary end-point is intimai thickness and extent of plaque in the carotid arteries as measured by B-mode ultrasonography.
Similar content being viewed by others
References
Chellingsworth MC, Willis JV, Jack DB, Kendall MJ. Pharmacokinetics and pharmacology of isradipine (PN 200-110) in young and elderly patients. American Journal of Medicine 84(Suppl. 3B): 72–79, 1988
Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 335: 827–838, 1990
Fleckenstein A. Model experiments on anticalcinotic and antiatherosclerotic arterial protection with calcium antagonists. American Journal of Cardiology 19(Suppl. 11): 109–121, 1986
Furberg CD, Byington RP, Borhani NA. For the MIDAS Research Group. Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine 86(Suppl. 4A): 37–39, 1987
Habib JB, Bossaller C, Wells S, Williams C, Morrisett JD, et al. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium channel blocker, PN-200-110. Circulation Research 58: 305–309, 1986
Heider JG, Weinstein DB, Pickens CE, Lan S, Su CM. Antiatherogenic activity of calcium channel blocker isradipine (PN-200-110): a novel effect on matrix synthesis independent of calcium channel blockade. Transplantation Proceedings 19(Suppl. 5): 96–101, 1987
Hof RP, Ruegg U. Pharmacology of the new calcium antagonist isradipine and its metabolites. American Journal of Medicine 84(Suppl. 3B): 13–17, 1988
Orekhov AN, Tertov VV, Kashimov KA, Kudryashov SS, Smirnov VN. Evidence of antiatherosclerotic action of verapamil from direct effects in arterial cells. American Journal of Cardiology 59: 495–496, 1987
Persson B, Andersson OK, Wysocki M, Hedner T, Aurell M. Renal and hemodynamic effects of isradipine in essential hypertension. American Journal of Medicine 86(Suppl. 4A): 60–64, 1989
Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists. American Journal of Cardiology 59: 163B–172B, 1987
Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists. American Journal of Medicine 86(Suppl. 4A): 27–32, 1989
Williamson KC, Tauber AL, Navarro J. Amlodipine inhibits formyl-methionyl-leucylphenylalanine receptor-coupled calcium transport in human neutrophils. Journal of Leukocyte Biology 42: 239–244, 1987
Author information
Authors and Affiliations
Consortia
Additional information
For a list of participating institutions, see p. 43.
Rights and permissions
About this article
Cite this article
Grimm, R.H., Flack, J.M., Byington, R. et al. A Comparison of Antihypertensive Drug Effects on the Progression of Extracranial Carotid Atherosclerosis. Drugs 40 (Suppl 2), 38–43 (1990). https://doi.org/10.2165/00003495-199000402-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199000402-00011